Andere Sprachen Kazia Therapeutics Limited

Aktien

A2JSLD

US48669G1058

KZIA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
0.272 ^USD	-3.72%		-26.49%	-38.11%

01.05.	Kazia Therapeutics Limited meldet erfolgreichen Abschluss der Phase 1 der klinischen Studie EVT801 bei Patienten mit fortgeschrittenem Krebs	CI
27.03.	Kazia Therapeutics Limited berichtet über die Ergebnisse für das am 31. Dezember 2023 endende Halbjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS	01.05.
Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	01.05.
Kazia Therapeutics : Purchase Agreement - Form 6-K	19.04.
Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP	19.04.
Kazia Therapeutics : Corporate Presentation	12.04.
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27.03.
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K	27.03.
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	21.03.
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	21.03.
Kazia Therapeutics : EVT801 Progress Update Presentation	19.03.
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA	27.02.
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	21.02.
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	21.02.
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21.02.
Certain Warrants of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04.02.
Certain Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04.02.
Certain American Depositary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	04.02.
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS	18.01.
Kazia Therapeutics Limited Announces Appointment of Board Members	18.01.
Kazia Therapeutics Limited Announces Resignation of Karen Krumeich as Chief Financial Officer	12.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Kazia Therapeutics Limited

Aktien

A2JSLD

US48669G1058

KZIA

Andere Sprachen

Filter